Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.

Virginia Arechavala-Gomeza¹, Maria Kinali¹,², L Feng¹, Michela Guglieri³, Geraldine Edge⁴, Marion Main¹, David Hunt⁵, Jan Lehovsky⁶ Volker Straub³, Kate Bushby³, Caroline Sewry¹,⁷, Jennifer Morgan¹, Francesco Muntoni¹.

¹The Dubowitz Neuromuscular Centre, Institute of Child Health, University College London, ²Department of Pediatrics, Hammersmith Hospital, London ³Institute of Human Genetics, Newcastle University, Newcastle, UK ⁴Department of Anaesthetics, Stanmore Hospital, London ⁵Department of Orthopaedics, St. Mary's Hospital, London, ⁶Department of Orthopaedics, Stanmore Hospital, London, ⁷Centre for Inherited Neuromuscular Diseases, RIAH Orthopaedic Hospital, Oswestry

Abstract

Duchenne Muscular Dystrophy (DMD) is characterised by the absence of dystrophin in muscle biopsies, although residual dystrophin can be present, either as dystrophin positive (revertant) fibres or traces. As restoration of dystrophin expression is the end point of clinical trials, such residual dystrophin is a key factor in recruitment of patients and may also confound the analysis of dystrophin restoration in treated patients, if, as previously observed in the mdx mouse, revertant fibres increase with age. In 62% of the diagnostic biopsies reports of 65 DMD patients studied, traces or revertants were recorded with no correlation between traces or revertants, the patients’ performance, or corticosteroids response. In nine of these patients, there was no increase in traces or revertants in biopsies taken a mean of 8.23 years (5.8-10.4 years) after the original diagnostic biopsy. This information should help in the design and execution of clinical trials focused on dystrophin restoration strategies.

Keywords: Duchenne Muscular Dystrophy ; Revertant fibres ; Dystrophin expression

Introduction

Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene that prevent the production of functional dystrophin. These mutations (both large rearrangements or small mutations) cause a disruption of the open reading frame (ORF) impeding the correct protein translation in DMD patients [1]. In the milder Becker muscular dystrophy (BMD) intragenic mutations that maintain the dystrophin mRNA ORF give rise to internally-deleted but partially functional dystrophins [1,2]. The diagnosis of DMD is corroborated by the demonstration of absent dystrophin. In muscle biopsy sections immunolabelled with antibodies to dystrophin, this is reflected as a dystrophin-negative background [3]. However, very rare, strikingly dystrophin-positive fibres [4] observed singly or in clusters, have been described in approximately 50% of DMD cases [1,4-10]. These “revertant fibres” [11] are also present in the mdx mouse [4] and the golden retriever dystrophic dog (GRMD) animal models [12]. The percentage of revertant fibres reported in diagnostic biopsies from DMD patients ranges from 0.01 to 7% [7-9,11,13-15] while in the mdx mouse they account for less than 1% of all muscle fibres [4,16]. A less reported though well known phenomenon [17] is the presence of traces of dystrophin, described as patches of below-normal dystrophin-positive areas visible at the sarcolemma of muscle fibres, seen in approximately 20% of DMD patients [6,17]. Traces may be present in up to 25% of the fibres [17] in DMD patients but do not appear to occur in the mdx mouse [18]. It is not known if these traces of dystrophin have a functional effect. [13] The extent and coexistence of revertant fibres and dystrophin...
traces have not been well characterized in DMD boys.

Revertant fibres have internally-deleted dystrophins, which skip frame-shifting normal exons inducing favourable skipping events and restoring the ORF in DMD patients [19]. These revertant dystrophins often lack the exon domains flanking deletions [11,13,20] and in the \textit{mdx} mouse the mutated exon 23 [19] but conserve the N and C terminal domains [11] allowing them to be correctly localized to the sarcolemma [21]. Studies in both DMD patients [14,22] and the \textit{mdx} mouse [18,19,23] have shown that an individual may harbor several types of revertant fibres, consisting of different internally deleted dystrophins. Proposed mechanisms of their generation include somatic reversion [24] and alternative splicing [9,19], the latter described in the coding region of the DMD gene in both patients and unaffected individuals [20]. As an endpoint in several ongoing clinical trials in DMD is the restoration of dystrophin expression [25-27], the interpretation of pre-existing residual dystrophin expression (both revertant fibres and trace expression) is important when assessing the efficiency of the therapeutic intervention. If revertant fibres increased in number with age, this may confound the interpretation of the intervention, especially in studies lasting several years and in which the increase of dystrophin is only limited.

Our study provides essential information on the residual dystrophin expression in a relatively large population of DMD patients. We firstly performed a detailed analysis of the previous diagnostic biopsy reports to assess the frequency of revertant fibres and dystrophin traces, and correlated the dystrophin expression findings to the severity of the disease progression. Finally, in a subset of patients we studied the presence of traces and revertant fibres over time in different muscles (original diagnostic quadriceps compared with extensor digitorum brevis, EDB, or paraspinal muscles).

**Materials and Methods**

**DMD patients**

All patients in this study had been diagnosed and followed up at the Dubowitz Neuromuscular Centre at Hammersmith Hospital, London, recently relocated to the Institute of Child Health & Great Ormond Street Hospital for Children, London, and at the Institute of Human Genetics in Newcastle, both tertiary referral centres for children with neuromuscular disorders. All patients presented with a DMD clinical picture, confirmed by an elevated serum CK, a DMD gene deletion and absence of dystrophin from the majority of fibres in a muscle biopsy [28]. Patients had detailed assessments of muscle strength and functional abilities using the Hammersmith Motor Ability Score (MAS) (maximum score 40) [29]. MAS deteriorates with advancing age and stabilizes or improves with steroid treatment [29,30]. We collected data on the MAS at baseline and within the first 3-6 months, i.e. at the first clinic review following the initiation of prednisolone therapy. We correlated the presence of residual dystrophin expression with the best MAS and the patient’s age prior to any intervention including the onset of prednisolone.

**DMD muscle biopsies**

Diagnostic biopsies (needle or open) were obtained from quadriceps muscles. In a subset of nine wheelchair-dependent patients (mean age 11.9 years), the extensor digitorum brevis (EDB) muscles were collected several years after (mean 8.23 years) their diagnostic biopsies during surgery for an orthopaedic procedure (Supplementary table 1). Muscle biopsy specimens were mounted in OCT, frozen by immersion in isopentane cooled in liquid nitrogen and stored at -80°C. Control sections were taken from a thigh muscle biopsy of a 41-year old female, with minimal myopathic changes. All muscle biopsies were processed by the same pathology team.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Mutation</th>
<th>Diagnostic biopsy</th>
<th>EDB biopsy</th>
<th>Time between biopsies (years)</th>
<th>Increase in revertants?</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Mutation exon 70</td>
<td>3 No revertants</td>
<td>13 Right EDB No revertants</td>
<td>10.4</td>
<td>No</td>
</tr>
<tr>
<td>Ab</td>
<td>Mutation exon 70</td>
<td>3 No revertants</td>
<td>13 Left EDB No revertants</td>
<td>10.4</td>
<td>No</td>
</tr>
<tr>
<td>B</td>
<td>Del exons 46-52</td>
<td>5 Revertant fibres</td>
<td>12 Revertant fibres</td>
<td>7.9</td>
<td>No</td>
</tr>
<tr>
<td>C</td>
<td>Del exons 3-13</td>
<td>4 Revertant fibres</td>
<td>12 Revertant fibres</td>
<td>6.9</td>
<td>No</td>
</tr>
<tr>
<td>D</td>
<td>Del exons 44</td>
<td>3 Revertant fibres</td>
<td>10 Revertant fibres</td>
<td>6.4</td>
<td>No</td>
</tr>
<tr>
<td>E</td>
<td>Del exons 50-53</td>
<td>2 No revertants</td>
<td>8 One revertant</td>
<td>6</td>
<td>No*</td>
</tr>
<tr>
<td>F</td>
<td>Del exons 45-52</td>
<td>4 Faint traces</td>
<td>11 Occasional traces</td>
<td>7</td>
<td>No</td>
</tr>
<tr>
<td>G</td>
<td>Del exons 46-51</td>
<td>5.6 Revertant fibres</td>
<td>12 Revertant fibres</td>
<td>6.7</td>
<td>No</td>
</tr>
<tr>
<td>H</td>
<td>Del exon 50</td>
<td>8 Traces and revertants</td>
<td>16 Traces and revertants</td>
<td>8.8</td>
<td>No</td>
</tr>
<tr>
<td>I</td>
<td>Del exon 50</td>
<td>7 No revertants, faint traces</td>
<td>13 Some revertants and faint traces</td>
<td>5.8</td>
<td>No*</td>
</tr>
</tbody>
</table>

Table 1: Transcript of the reports of the subset of nine patients who were biopsied at two different times: original (quadriceps) diagnostic biopsy and EDB biopsy. *Patient E’s single revertant fibre in the second biopsy represents a negligible increase. Patient I showed traces in the original biopsy and revertants and traces in the second one.

**Immunohistochemistry**

Unfixed frozen sections (6 µm) were incubated with primary antibodies for 1h at room temperature, followed by three washes in PBS, and incubation with biotinylated secondary anti-mouse or anti-rabbit antibodies (Amersham UK, 1:200) for 1h at room temperature. Samples were then incubated with streptavidin conjugated to Alexa 594 (Invitrogen UK, 1:1000) for 15 min at room temperature and washed in PBS before mounting in Histomount (National Diagnostics). All samples were examined and photographed with a Leica epifluorescent microscope.

The antibodies systematically used were: Dys 3 (exon 13) (1:10), Dys 2 (last 17 amino acids of C-terminus) (1:20) [31] and Utrophin (DRP2 1:5). In a subset of samples the following antibodies were additionally used: β-Dystroglycan (BDG), α-sarcoglycan (ASG), spectrin and dystrophin (Dys1, (rod domain), P7 (rod domain, exons 56-60) [32] and Mandys106 (rod domain, exon 43) [33]. All primary antibodies except P7, a rabbit polyclonal antibody [32,34] were monoclonal antibodies from Novocastra Laboratories Ltd except MANDYS106 (gift from Prof. G. Morris, Oswestry).

**Study of the biopsy reports**

The same pathologist, CAS, reported all muscle biopsies in an 8-year period and systematically commented on traces and revertants (Supplementary table 1). To validate her analysis, the immunohistochemical analysis in a subset of 10 patients was repeated, analyzed blindly by two other researchers (LF and VA) and compared to the original reports (Supplementary table 2).

When a second biopsy was collected from 9 patients, it was studied and reported by the same pathologist. When studying the incidence of residual dystrophin in our patients, only the original diagnostic reports were included in the analysis, to avoid duplication.

**Relative intensity measurements**

New sections from the sixteen biopsies used for quantification were stained and analysed under epifluorescence using a Leica DMR microscope linked to Metamorph (Universal
Imaging Inc., Downington, PA) as described previously[35]. To summarize, each sample was studied with all eight different antibodies and four images captured per antibody. In all experiments, sections from control and experimental muscles were immunostained simultaneously and, for each antibody except utrophin, used to set the capture settings for the DMD samples. Four images were captured in each section and captured images were analyzed by the Metamorph program, to measure intensities of different areas (Supplementary figure 1). Ten different regions of interests (ROIs), each in a different fibre, were randomly selected per image. These regions included both the cytoplasm and the sarcolemma of fibres, so that a maximum value corresponding to the sarcolemma and a minimum value corresponding to the cytoplasm were used in the analysis. In total, for each experiment, 40 different measurements were taken per antibody per sample. Measurements of the intensity of spectrin from serial sections were used as an internal control to normalise the measurements and these were expressed as a percentage of the control for illustration purposes.

Data analysis
Statistical analysis was performed with the SPSS package (SPSS Inc, USA). Mann-Whitney analysis was used to compare the groups.

Results
Revertant fibres are common, but represent a very low percentage of total muscle fibres in DMD muscle.

Biopsy reports were examined for references to residual dystrophin expression. The results were divided into “no revertant fibres and no traces present”, “traces of dystrophin only”, “revertant fibres only” and “revertant fibres and traces”. Of 63 DMD biopsy reports examined, 47% presented revertant fibers, 32% traces and 36% had neither. 15% showed both revertant fibres and traces. In the revertant group, 19% had only one revertant fiber (9% of total samples), with the rest described as having “several” as the only reference to the quantity of revertant fibres. This last group represents 38% of the total.

No correlation between revertant fibres or traces and Motor Ability Score
Data on the best MAS and the patient’s age before prednisone treatment was initiated were available for 35/63 (55%) patients. Residual dystrophin was mentioned in the muscle biopsy reports of 18 of these patients, but not in the remaining 17 patients. Both patients’ groups demonstrated similar MAS (Figure 1a).

![Figure 1](image)

Figure 1 A) Best Motor Ability Score of DMD patients whilst steroid naïve versus natural history data. B) Motor Ability Score of DMD patients with and without dystrophin residual expression revertants at baseline and within 3-6 months of steroid treatment.

Data on the best MAS and the corresponding patient’s age at the baseline (before starting steroids) and at the first follow-up (within 3-6 months) of prednisolone treatment were available for 28/63 (44%) of the patients. Ten patients had no residual dystrophin and were started on prednisolone at 5.68±1.68 years and further 18 had residual dystrophin and were started on prednisolone at 6.84±1.71 years (age at onset not significantly different). Prednisolone was given as an intermittent
Figure 2 Intensity measurements of images captured from sections of 17 biopsies taken from different patients, after immunostaining with Dys2 were analysed using a semi-quantitative method.

A) The intensity of Dys2 immunostaining is shown as a percentage of the control (2) sample. Arrows show samples that were referred to as containing traces in the reports. Those samples in which revertant fibres were reported are highlighted with the # symbol. Error bars +/- 2 s.e.m.

B) Sections immunostained with Dys2 showed significant differences (p<0.001) between those that were reported to have neither traces or revertant fibres (A) and those that were reported to have revertant fibres only (B), or traces only (C), or both revertant fibres and traces (D).
regime using either a regime of 10 days on and 10 days off (11/13 in the group with no residual dystrophin and 13/15 in the group with residual dystrophin) or a regime of 10 days on and 20 days off (2/13 in the residual dystrophin group and 2/15 in the residual dystrophin group). The dose was kept at 0.75mg/kg/day regardless of the regime. There was no difference in the patients’ response to prednisolone at 3-6 months between those who had residual dystrophin or not (Figure 1b).

The level of trace dystrophin expression can be measured semi-quantitatively using the Metamorph programme

The results of the intensity analysis of the biopsies were compared with the references to traces found in their histopathological reports (n=16). Relative quantitative intensity measurements were higher in those samples that had been reported as containing traces than those which reports did not mention traces (Figure 2a). When samples were grouped according to the presence of either revertant fibres or traces, those that had been labeled as containing neither revertant fibres or traces showed significantly less relative intensity than the other groups (one way ANOVA, p<0.001) (Figure 2b).

**Figure 3** Cryosections from quadriceps muscle biopsies from: muscle from a patient with a deletion in dystrophin exons 46-51 taken at diagnosis (panels A-F) and six years later (panels G-L) stained with antibodies to dystrophin: Dys1 (A and G), Dys2 (B and H), Dys3 (C and I) and P7 (D), alpha-sarcoglycan (E and J), beta-dystroglycan (F and K) and utrophin (L). A cluster of revertant, dystrophin-positive fibres is seen in each series of sections. Revertant fibres also contain alpha-sarcoglycan (E and J) and beta-dystroglycan (F and K). Utrophin is expressed in the dystrophin-negative muscle fibres, but is down-regulated in the revertant fibres (L).

Correspondence to: Jennifer Morgan, The Dubowitz Neuromuscular Centre, 1st Floor, UCL Institute of Child Health, 30 Guilford Street, London, WC1N EH Tel: +44 (0)20 7905 2874, Fax: +44 (0)20 7905 2832; j.morgan@ich.ucl.ac.uk
β-dystroglycan and α-sarcoglycan are co-expressed at higher levels in revertant fibers

When analysed by immunohistochemical techniques, revertant fibres were easily identifiable from the fibres surrounding them, with antdystrophin antibodies as they had strong staining with the Dys1, Dys2 and Dys3 antibodies used in the diagnostic panel. In addition revertant fibres also had higher levels of the proteins of the dystrophin associated complex β-dystroglycan and α-sarcoglycan. The opposite phenomenon was observed in the case of utrophin, which was present at a higher level in fibres surrounding revertant fibres than in the revertant fibres themselves. This was clearly visible in both diagnostic quadriceps and EDB biopsies collected years after diagnosis (Figure 3). Intriguingly, in the muscle biopsy from a different patient with a deletion in exons 45-50 (Patient 65, Supplementary table 1), a cluster of revertant fibres that was recognised with Dys 2 and Dys3, but not Dys1 and Mandys106 antibodies, was surrounded by fibres with traces of dystrophin, recognised by Mandys106 antibody, which binds to exon 43, but not the other antibodies (Figure 4). This clearly illustrates that, in this muscle biopsy, different epitopes are expressed by the revertant fibres and the fibres containing dystrophin traces, indicating that the mechanisms involved in dystrophin expression in these two types of fibre can be different.

The number of revertant fibres and amount of traces do not change with time.

Quadriceps muscle biopsies that had been collected at the time of diagnosis were compared with the EDB muscle biopsies obtained several years later (average 7.3 years later). It was observed that those patients whose original biopsy report mentioned revertant fibres or traces presented the same features in the report of the more recent EDB biopsy (Figure 3 and Table 2). In one particular patient, we cut new sections, stained them and compared three muscle samples: the original quadriceps biopsy and both the EDB and the paraspinal muscle biopsies obtained 6.7 years later at the time of spinal fusion. In this patient, the dystrophin expression observed in the quadriceps correlated very closely with the EDB and paraspinal muscle (Patient G in tables 1 and supplementary table 1).

Discussion

Several studies have previously reported the pattern of dystrophin expression in DMD patients; the notion that up to 50% of them have revertant fibres is fully acknowledged in the literature [1,5,6,8-10]. Less emphasis has been placed on the expression of dystrophin traces in DMD. While from a diagnostic perspective revertants and traces do not produce any difficulty, their occurrence could make the interpretation and quantification of efficacy of experimental therapies
complicated. Indeed a number of different therapeutic strategies aiming to restore dystrophin expression are currently being trialed in DMD: these include i) antisense oligonucleotides which induce exon skipping in DMD patients with out-of-frame deletions; ii) PTC124, which is thought to enable the translation machinery to bypass nonsense mutations; iii) adeno-associated viruses coding for mini-dystrophins; iv) plasmid DNA injection of dystrophin [36]. In these early studies, restoration of dystrophin expression following therapy might be relatively limited, especially in boys receiving low doses of medicinal product in dose escalation studies. The possibility that traces of dystrophin or revertant fibres may be present in different percentages in different muscles of the body, or that this expression could increase with age [19], also needs to be considered. Our study was therefore aimed to provide more information on these aspects, by studying the prevalence of revertant fibres and traces in a large population of DMD patients. We found revertant fibres in 47% of the patients, which corresponds with figures reported in previous studies. When traces were also considered, residual dystrophin was found in 64% of the patients studied. 15% of biopsies studied had both strongly-staining revertant fibres and fibres containing unequivocal, but less intense, dystrophin staining (traces), showing that both types of fibres may, but not necessarily, be present in the same muscle. These dystrophins cannot be distinguished from each other by immunoblotting; in addition, western blots may not be sensitive enough to detect very small amounts of dystrophin produced in either revertant fibres or traces, nor quantitative enough at the high and low end of the signal [38]. Western blotting requires more muscle than immunostaining and there was insufficient muscle from several patients to perform this analysis. Despite limitations also of this technique, immunostaining has been used in many studies in a semi-quantitative manner [25,26]; in addition the number of dystrophin positive fibres in a representative section of muscle has been shown to correlate with the amount of dystrophin on a western blot [37]. A problem with both western blotting and immunostaining is sensitivity and specificity of the antibodies used. Those we have used in this study are very specific and are widely-used in routine diagnosis [3,38], but some are clearly more sensitive than others [25]. The problem is compounded in studies of revertant fibres, which express lower than normal levels of dystrophin [35] and only express some epitopes of the protein [19]. After consideration of all advantages and drawbacks of immunostaining and western blotting, we chose to use immunostaining, rather than western blotting, for our study.

Studies in the mdx mouse suggest that revertant fibres could increase in number with age [19] and anecdotal evidence was found in some human studies showing a higher percentage of revertant fibres in older patients [8,13]. This could be relevant as it might confuse the analysis of dystrophin restoration in treated patients. Fanin et al. (1992)[8] found more than 1% dystrophin-positive fibres only in DMD patients over 6 years of age and the same group (1995) [13] reported that older patients had more revertant fibres per cluster and that there was a direct correlation between the age of the patient and prevalence of the percentage of total fibres that were dystrophin positive. However a limitation of that study, performed in 49 individuals, is that the majority of the biopsies were from patients under 10 years of age and the lack of longitudinal data on the same patients. In addition, this study reported the percentage, not the number, of dystrophin positive fibres. If the presence of dystrophin confers a survival advantage to the fibre, dystrophin negative fibres will be lost, whereas dystrophin positive fibres will survive, which may lead to an increase in the percentage, but not the total number, of dystrophin positive fibres with time.

In our study, we compared quadriceps biopsies with EDB biopsies performed in the
same patients 6-10 years later and find no
obvious increase in numbers of dystrophin
positive fibres, nor did we find larger clusters
of revertant fibres at the later timepoint.
Those patients who had no dystrophin in the
original biopsy did not have any in the second
biopsy and vice versa.

The apparent lack of expansion of revertant
clusters in human DMD muscle may be due to
either lack of functional muscle stem cells, or
to the environment within DMD muscle being
sub-optimal for stem cell function. In mice,
expansion of revertant fibres, which appears
to be a clonal event, is dependent on muscle
regeneration [39] and does not occur under
conditions in which muscle stem cells are
either ablated or not activated [40].

There is ongoing discussion about the
possibility that dystrophin-positive fibres may
offer a biological advantage by lessening the
severity of the disease course in DMD
[13,17,41]. We therefore correlated
dystrophin expression both with the
functional abilities of patients as assessed by
the MAS, whilst steroid naïve, and with
response to corticosteroid treatment.
Although our results should be interpreted
with caution, as only 55% of patients had
detailed assessments at the peak of their
motor ability whilst steroid naïve, our data do
not indicate a difference in function between
patients with or without residual dystrophin
expression. Different explanations could
account for these findings. One possibility is
that the dystrophin produced in these fibres,
although correctly located, is lacking crucial
binding domains, and is therefore not able to
efficiently protect the fibre from damage.
Indeed, internally deleted dystrophins lacking
an appreciable portion of the rod domain are
ineffective in reducing myofibre necrosis and
restoring muscle function in transgenic mdx
mice [42-45]. Another possibility is that this
phenomenon occurs in so few fibres that it is
not sufficient to be beneficial to properties of
the entire muscle. It is quite likely that the
amount of residual dystrophin had not
reached the threshold level of protein
necessary to effect a functional improvement
in these patients [46].

In previous studies, DMD muscles containing
traces and revertant fibres have been
analysed by western blotting and shown to
contain higher amounts of dystrophin than
muscles without either, but traces or
revertant fibres could not be studied
separately [17]. We have shown that the
presence of traces can be identified not only
by visual inspection of the muscle biopsy
slides but also by a semi-quantitative
capturing method, that reveals dystrophin
protein to be significantly higher in fibres with
dystrophin traces compared to the
neighboring ones [25,26]. The mechanism
responsible for the production of dystrophin
traces may well be different from revertant
fibres, but in both cases, dystrophin is
correctly localized at the sarcolemma. The
molecular basis of trace dystrophin expression
remains to be elucidated, but we show that, in
a biopsy of a patient with a deletion in exons
45-50, a cluster of revertant fibres expresses
different dystrophin epitopes than the
surrounding fibres that contain traces of
dystrophin. This suggests that the dystrophin
proteins produced in this group of fibres may
have been produced by different mechanisms
in this patient.

One limitation of our study is that we have not
been able to study the same muscle analysed
in the original diagnostic biopsy, but
compared dystrophin expression of this
muscle with the EDB muscle. While we cannot
exclude the possibility that a repeated
quadriceps biopsy might have shown a
different percentage of fibres with residual
expression, the very close correlation
between the presence of dystrophin in the
two biopsies (and also a third paraspinal
muscle biopsy in a single patient) is very
encouraging and makes this possibility
unlikely. In addition, the histological analysis
of the EDB muscle showed a clear advanced
dystrophic pathology in all patients,
suggested that the degeneration and regenerative process does occur indeed in this muscle as well [25].

We conclude that dystrophin expression, either in revertant fibres, or in fibres containing trace amounts of dystrophin, is common phenomenon in DMD patients but, in contrast to the mdx mouse, we found no evidence of clonal expansion of revertant fibres over time, at least when comparing different muscles. This lack of increase in number of dystrophin-containing fibres with age will facilitate the interpretation of strategies designed to restore dystrophin expression and facilitates the recruitment of patients into experimental therapies, provided the patient had already had a diagnostic biopsy.

References


